From Fancy to Future: Efung Capital's Zhu Pai Named to Pedata's 2025 "F40 China Young Investors"

Date： 2025-11-28

Recently, Pedata, the entrepreneurship and investment information platform under Zero2IPO Holdings, officially announced its 2025 "F40 China Young Investors" list. Efung Capital CEO Zhu Pai was named to the list.

The "F40 China Young Investors" selection has been held for eight consecutive years. The "F" stands for Fancy, representing boundless imagination, and also for Future, representing forward-looking vision. This list is dedicated to recognizing outstanding young investors under the age of 40 in China, uncovering the brave "catchers" behind unicorn companies, and documenting the inspiring stories unfolding in the world of technology and business.

Looking ahead, Efung Capital will continue to focus on cutting-edge global biotechnologies, upholding this spirit of "Fancy" imagination and "Future" foresight. We will forge ahead through the waves of the global biopharmaceutical industry, continuing to discover and nurture industry unicorns, and contributing the power and wisdom of capital to the healthcare industry in China and around the world.

Previous：Monthly Health Read | November 2025Next：Xunlu Bio's Fucaso® Approved by Hong Kon

Related News / Recommended news More

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration

2026 - 03 - 24

In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

2026 - 03 - 25

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

2026 - 03 - 05

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...